z-logo
open-access-imgOpen Access
Spectrum of FGFR2/3 Alterations in Cell-Free DNA of Patients with Advanced Urothelial Carcinoma
Author(s) -
Petros Grivas,
Lesli A. Kiedrowski,
Guru Sonpavde,
Sumati Gupta,
Roby Thomas,
Theodore Stewart Gourdin,
Aaron Hardin,
Kimberly M. Hamann,
Bishoy Faltas,
Nicholas J. Vogelzang
Publication year - 2021
Publication title -
bladder cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.27
H-Index - 19
eISSN - 2352-3735
pISSN - 2352-3727
DOI - 10.3233/blc-201517
Subject(s) - targeted therapy , refractory (planetary science) , medicine , cancer research , oncology , urothelial carcinoma , carcinoma , renal cell carcinoma , cancer , biology , bladder cancer , astrobiology
Detecting genomic alterations (GAs) in advanced urothelial carcinoma (aUC) can expand treatment options by identifying candidates for targeted therapies. Erdafitinib is FDA-approved for patients with platinum-refractory aUC with activating mutation or fusion in FGFR2/3. We explored the prevalence and spectrum of FGFR2/3 GAs identified with plasma cfDNA NGS testing (Guardant360) in 997 patients with aUC. FGFR2/3 GAs were detected in 201 patients (20%) with characterized activating GAs in 141 (14%). Our results indicate the Guardant360-based FGFR2/3 GA detection rate is similar to those described from previous studies employing tumor tissue testing, suggesting that plasma-based cfDNA NGS may non-invasively identify candidates for anti-FGFR targeted therapies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here